Intracranial and subcortical volumes in adolescents with early-onset psychosis: A multisite mega-analysis from the ENIGMA consortium

Tiril P. Gurholt1,2,3 | Vera Lonning2,3 | Stener Nerland2,3 | Kjetil N. Jørgensen2,3 | Unn K. Haukvik1,4 | Clara Alloza5 | Celso Arango5,6 | Claudia Barth2 | Carrie E. Bearden7,8 | Michael Berk9,10 | Hannes Bohman11,12,13 | Orwa Dandash9 | Covadonga M. Díaz-Caneja5,6 | Carl T. Edbom11 | Theo G. M. van Erp14,15 | Anne-Kathrin J. Fett16,17,18 | Sophia Frangou19 | Benjamin I. Goldstein20,21 | Anahit Grigorian | Neda Jahanshad22 | Anthony C. James23,24 | Joost Janssen5,6 | Cecile Johannessen2 | Katherine H. Karlsgodt8,25 | Matthew J. Kempton26 | Peter Kochunov27 | Lydia Krabbendam18 | Marinos Kyriakopoulos28,29 | Mathias Lundberg11,12,13,30 | Bradley J. MacIntosh31,32 | Bjørn Rishovd Rund33,34 | Runar E. Smelror2,3 | Alysha Sultan19,35 | Christian K. Tannes2,36 | Sophia I. Thomopoulos21 | Ariana Vajdi7 | Kirsten Wedervang-Resell1 | Anne M. Myhre37,38 | Ole A. Andreassen1,2 | Paul M. Thompson21 | Ingrid Agartz2,3,11 | For the ENIGMA-EOP Working Group

1Norwegian Center for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
2Norwegian Center for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
4Department of Adult Mental Health, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, iISGM, CIBERSAM, Madrid, Spain
6School of Medicine, Universidad Complutense, Madrid, Spain
7Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California
8Department of Psychology, UCLA, Los Angeles, California
9IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia
10Orygen Youth Health Research Center, The Florey Institute for Neuroscience and Department of Psychiatry, Parkville, Victoria, Australia
11Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden, Stockholm, Sweden
12Department of Neuroscience, Child and Adolescent Psychiatry, Uppsala University, Uppsala, Sweden
13Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
14Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California
15Center for the Neurobiology of Learning, University of California Irvine and Memory, Irvine, California
16Department of Psychology, City, University of London, London, UK

Received: 31 July 2020 | Revised: 11 September 2020 | Accepted: 13 September 2020
DOI: 10.1002/hbm.25212

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
Abstract

Early-onset psychosis disorders are serious mental disorders arising before the age of 18 years. Here, we investigate the largest neuroimaging dataset, to date, of patients with early-onset psychosis and healthy controls for differences in intracranial and subcortical brain volumes. The sample included 263 patients with early-onset psychosis (mean age: 16.4 ± 1.4 years, mean illness duration: 1.5 ± 1.4 years, 39.2% female) and 359 healthy controls (mean age: 15.9 ± 1.7 years, 45.4% female) with magnetic resonance imaging data, pooled from 11 clinical cohorts. Patients were diagnosed with early-onset schizophrenia (n = 183), affective psychosis (n = 39), or other psychotic disorders (n = 41). We used linear mixed-effects models to investigate differences in intracranial and subcortical volumes across the patient sample, diagnostic subgroup and antipsychotic medication, relative to controls. We observed significantly lower intracranial volume (Cohen’s $d = -0.39$) and hippocampal ($d = -0.25$) volumes, and higher caudate ($d = 0.25$) and pallidum ($d = 0.24$) volumes in patients relative to controls. Intracranial volume was lower in both early-onset schizophrenia ($d = -0.34$) and affective psychosis ($d = -0.24$), and early-onset schizophrenia showed lower hippocampal ($d = -0.24$) and higher pallidum ($d = 0.29$) volumes. Patients who were currently treated with antipsychotic medication (n = 193) had significantly lower intracranial volume ($d = -0.42$). The findings demonstrate a similar pattern of brain alterations in early-onset psychosis as previously reported in adult psychosis, but with notably low intracranial volume. The low intracranial volume suggests disrupted neurodevelopment in adolescent early-onset psychosis.
1 | INTRODUCTION

Early-onset psychosis (EOP) disorders, defined as psychotic disorders with onset of the first psychotic episode before age 18 years, affect 0.05–0.5% of the population (Boeing et al., 2007; Dalsgaard et al., 2019; Gillberg, Wahlström, Forsman, Hellgren, & Gillberg, 1986; Sikich, 2013), and have a heterogeneous clinical presentation. They are debilitating mental disorders and constitute one of the leading causes of lifetime disease burden for adolescents (Gore et al., 2011). With the exception of some prior multi-site studies (Arago et al., 2012; Fraguas, Díaz-Caneja, Pina-Camacho, Janssen, & Arango, 2016; Reig et al., 2011), structural brain magnetic resonance imaging (MRI) studies in EOP are limited by small sample sizes and low statistical power, typically including fewer than 50 patients. To overcome these limitations, the Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA) meta-analyses in adult schizophrenia (van Erp et al., 2016) has been shown (Andersen et al., 2020; di Sero et al., 2019). This proposed mechanism is likely mediated by the dopamine D2 receptor (Guma et al., 2018), and the neurobiological responses may differ as a function of neurodevelopmental phase (Moe, Medely, Reeks, Burne, & Eyles, 2017). In patients with childhood-onset schizophrenia (i.e., onset before age 13 years) investigated during adolescence, pallidum volumes enlarged with neuroleptic exposure (Frazier et al., 1996a) while transfer to clozapine treatment was associated with caudate volume reduction (Frazier et al., 1996b). In early-onset schizophrenia (i.e., onset before age 18 years), antipsychotic medication use was associated with ventricular enlargement but not with higher caudate volumes (Juuhl-Langseth et al., 2012).

The aim of this study was to robustly identify differences in ICV and subcortical volumes using a mega-analytical approach of the hitherto largest neuroimaging sample of adolescent patients with EOP and healthy controls. We performed subgroup analyses by dividing patients into three groups: (a) early-onset schizophrenia, (b) affective psychosis disorders, including bipolar and major depressive disorders with psychotic features, and (c) other psychoses, including psychosis not otherwise specified, and brief psychotic disorders. Based on prior adult studies (Hibar et al., 2016; Rimol et al., 2010; van Erp et al., 2016), we hypothesized lower ICV and volumetric subcortical abnormalities in EOP similar to those of adult psychosis when compared to healthy controls; with strongest effects in early-onset schizophrenia, and an attenuated but similar pattern in affective psychosis and other psychoses. Based on prior studies on antipsychotic treatment (Chakos et al., 1994; Chua et al., 2009; di Sero et al., 2019; Hashimoto et al., 2018; van Erp et al., 2016), we expected antipsychotic medication use in EOP to be associated with enlarged basal ganglia volumes.

ventricular volumes (Juuhl-Langseth et al., 2012), and higher caudate, putamen and pallidum volumes that correlated with neuroleptic treatment and age of onset (Frazier et al., 1996a). A study on early-onset bipolar disorder, where 61% of patients had psychosis symptoms, reported lower amygdala and higher putamen volumes (DelBello, Zimmerman, Mills, Getz, & Strakowski, 2004). It has been difficult to establish a consistent pattern of subcortical alterations in EOP from these studies, due to the limited number of previous studies and their relatively small sample sizes.

Antipsychotic treatment has been linked to basal ganglia volume increases in adult patients (Chakos et al., 1994; Chua et al., 2009; di Sero et al., 2019; Hashimoto et al., 2018; van Erp et al., 2016). Although not consistently replicated (Emsley et al., 2015), this finding may reflect striatal hypertrophy as a compensatory response to striatal dopamine receptor antagonism (Chua et al., 2009), the main target of antipsychotics, and a link between antipsychotic dose and basal ganglia volume has been shown (Andersen et al., 2020; di Sero et al., 2019). This proposed mechanism is likely mediated by the dopamine D2 receptor (Guma et al., 2018), and the neurobiological responses may differ as a function of neurodevelopmental phase (Moe, Medely, Reeks, Burne, & Eyles, 2017). In patients with childhood-onset schizophrenia (i.e., onset before age 13 years) investigated during adolescence, pallidum volumes enlarged with neuroleptic exposure (Frazier et al., 1996a) while transfer to clozapine treatment was associated with caudate volume reduction (Frazier et al., 1996b). In early-onset schizophrenia (i.e., onset before age 18 years), antipsychotic medication use was associated with ventricular enlargement but not with higher caudate volumes (Juuhl-Langseth et al., 2012).

KEYWORDS
adolescence, antipsychotics, brain structure, early-onset, intracranial volume, psychosis spectrum


2 MATERIALS AND METHODS

2.1 Study samples

Eleven cohorts with MRI data acquired on 16 scanners (1.5T: four scanners/223 scans; 3T: 12 scanners/399 scans) contributed to this study, yielding a combined sample of 263 patients with EOP and 359 healthy controls. The patient group included early-onset schizophrenia \( n = 183 \), affective psychosis \( n = 39 \), or other psychosis \( n = 41 \) according to DSM-IV (American Psychiatric Association, 2000) or ICD-10 (World Health Organization, 2004). Patients were between age 12 to 18 years at scan (14 had illness onset before age 12). Table 1 presents demographic and clinical information for the combined sample. Table S1 demonstrates cohort-wise demographic and clinical information, and Table S2 cohort-specific inclusion and exclusion criteria. Five sites shared positive and negative syndrome (PANSS; Kay, Fiszbein, & Opler, 1987) scores, while one site shared Scale for the Assessment of Negative/Positive Symptoms (SANS [Andreasen, 1983]/SAPS [Andreasen, 1984]) scores.

All participants, parents or legal guardians gave written informed consent or assent as appropriate. Each site had ethical approval from their local ethics committees or institutional review board to participate in the study and share anonymized data for mega-analysis. The study was conducted in accordance with the Helsinki Declaration.

2.2 MR imaging acquisition and processing

T1-weighted brain images were processed locally at each site with FreeSurfer (version 5.3.0; http://surfer.nmr.mgh.harvard.edu; Fischl, 2012) following standardized ENIGMA processing protocols (http://enigma.ini.usc.edu). See Table S3 for cohort/scanner-specific acquisition parameters. In the statistical analyses, we included the same brain measures as prior ENIGMA studies (Hibar et al., 2016; van Erp et al., 2016), namely estimated ICV (Buckner et al., 2004) and bilateral subcortical volumes: accumbens, amygdala, hippocampal, thalamus, lateral ventricle, caudate, pallidum, and putamen.

The segmentation quality was assessed following a standardized protocol by identifying outlier volumes at each site, which were excluded if the segmentation was deemed inaccurate after visual inspection (Note S1).

2.3 Statistical analyses

The demographic variables of patients and controls were compared using \( \chi^2 \)-test for categorical variables and t-test/two-sided Wilcoxon rank sum test for normally/non-normally distributed continuous variables. Normality was assessed using the Shapiro–Wilk test. We

### TABLE 1 Demographic and clinical information

<table>
<thead>
<tr>
<th></th>
<th>Patients (N = 263)</th>
<th>Controls (N = 359)</th>
<th>( \chi^2 )-test/Wilcoxon rank-sum test</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N (%)</td>
<td>103 (39.2%)</td>
<td>163 (45.4%)</td>
<td>2.2</td>
<td>.1410</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age ( a ) (years)</td>
<td>16.4 ± 1.4</td>
<td>15.9 ± 1.7</td>
<td>0.5</td>
<td>.0003</td>
</tr>
<tr>
<td>Age at onset ( b ) (years)</td>
<td>15.0 ± 1.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of illness ( b ) (years)</td>
<td>1.5 ± 1.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PANSS positive ( c )</td>
<td>18.9 ± 7.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PANSS negative ( c )</td>
<td>18.1 ± 7.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range (median)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>12-18.9 (16.7)</td>
<td>12-18.9 (16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age of onset ( b ) (years)</td>
<td>7.6-18.2 (15.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of illness ( b ) (years)</td>
<td>0-7.5 (1.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PANSS positive ( c )</td>
<td>7-46 (19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PANSS negative ( c )</td>
<td>7-43 (16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOS/AFP/OTP</td>
<td>183/39/41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP users/non-users ( d )</td>
<td>193/39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP users EOS/AFP/OTP ( d )</td>
<td>136/26/31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5T/3T</td>
<td>117/146</td>
<td>106/253</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: \( p \) values < .05 considered significant.

Abbreviations: AFP, affective psychosis; AP, antipsychotics; EOS, early-onset schizophrenia; OTP, other psychoses; PANSS, positive and negative syndrome scale.

\( a \)Not normally distributed, applied Wilcoxon rank-sum test.

\( b \)32 had missing AAO/DOI.

\( c \)90 had missing PANSS positive/negative scores.

\( d \)31 (30 EOS, one AFP) had missing information on current AP medication.
evaluated the distribution of the participants age (Figure S1) and brain volumes (Figure S2).

We investigated ICV and subcortical volumes mega-analytically with linear-mixed effects (LME) models (Laird & Ware, 1982) using the lme function (nlme package) in R (version 3.5.2; www.r-project.org). We adjusted for age, sex, and ICV (subcortical volumes only) as fixed-effects variables unless otherwise specified, and scanner as random-effects variable. Independent analyses were conducted for combined (averaged), and left/right hemispheric structures. We refer to combined structures unless otherwise specified.

In the main model, we investigated patient-control differences in ICV and subcortical volumes. For qualitative comparison of between-cohort heterogeneity, we included a complementary meta-analysis (Note S2). Follow-up analyses were performed for age-by-group or sex-by-group interactions. Additionally, we conducted follow-up analyses of the main model without adjusting for ICV to explore the relative difference in subcortical structures.

Next, we conducted follow-up analyses of the main LME model for patient characteristics on brain volumes. We stratified patients into early-onset schizophrenia, affective psychosis, and other psychoses, and compared each diagnostic subgroup to controls. Similarly, we stratified patients into current antipsychotic users and current non-users, and compared them to controls. Finally, in patients, we tested for effects of age at onset, duration of illness, and antipsychotic medication users versus non-users, on brain volumes. These analyses were adjusted for age, sex, and ICV as fixed-effects variables and scanner as random-effects variable.

We computed the Cohen’s d effect sizes from the t-statistics for categorical variables and via the partial correlation coefficient (r) for continuous variables (Nakagawa & Cuthill, 2007). We corrected for multiple comparisons using the false discovery rate (FDR; Benjamini & Hochberg, 1995) with α = 0.05 and computed a study-wide FDR threshold across N = (9 + 2*8)*(8 + 2) + (9 + 8*2)*3 = 325 tests, which is the number of reported combined, left- and right-hemisphere tests, leading us to consider p values ≤ 0.0062 as significant. Nominal significant p values (p ≤ 0.05) are reported. We report uncorrected p values. Tables S4–S15 present the results of the individual analyses.

3 | RESULTS

3.1 | Demographics and clinical information

Patients with EOP were significantly older than controls (Δ = 0.5, p = 3 × 10⁻⁶). The largest patient group was early-onset schizophrenia (69.5%), followed by other psychoses (15.6%), and affective psychosis (14.8%). The patients had mean illness duration 1.5 ± 1.4 years, age at onset 15.0 ± 1.9 years, and PANSS positive and negative scores of 18.9 ± 7.7 and 18.1 ± 7.6, respectively. 193 (73.4%) patients received current treatment with antipsychotic medication (Table 1). Split by diagnosis, 136 (74.3%) early-onset schizophrenia, 31 (75.6%) other psychoses, and 26 (66.7%) affective psychosis patients currently used antipsychotic medication.

3.2 | Case–control differences

EOP had significantly lower ICV (Cohen’s d = −0.39, p = 3 × 10⁻⁶) and hippocampal volume (d = −0.25, p = .003), higher caudate (d = 0.25, p = .002), and pallidum (d = 0.24, p = .004) volumes, and nominally significant lower amygdala (d = −0.2, p = .020), and higher lateral ventricular (d = 0.22, p = .010) volumes, compared to controls (Figure 1).

In split-hemisphere analyses, only structures of the left hemisphere were significantly altered, showing lower hippocampal (d = −0.24, p = .005), and higher caudate (d = 0.27, p = .001), pallidum (d = 0.28, p = 8e-04), and lateral ventricular (d = 0.24, p = .004) volumes (Table S4).

Follow-up analyses did not show significant age-by-group or sex-by-group interactions (Tables S5 and S6).

In follow-up analyses unadjusted for ICV, we observed significantly lower hippocampal (d = −0.42, p = 6 × 10⁻⁷), amygdala (d = −0.32, p = 2 × 10⁻⁴), thalamus (d = −0.32, p = 1 × 10⁻⁴), and accumbens (d = −0.25, p = .004) volumes in EOP relative to controls (Figure S3). Effects were similar bilaterally (Table S7).

The complementary meta-analysis of patient-control differences largely corroborated the results, but additionally showed significantly higher lateral ventricular volume (d = 0.3, p = 5 × 10⁻⁴), with similar effects bilaterally (Table S8). Forest plots illustrate the variability among cohorts (Figures S4–S6).

3.3 | Diagnostic subgroups

When stratifying by EOP diagnostic subgroups, both early-onset schizophrenia (d = −0.34, p = 1 × 10⁻⁵) and affective psychosis (d = −0.42, p = .003) showed lower ICV, while only early-onset schizophrenia showed significantly lower hippocampal (d = −0.24, p = .006) and higher pallidum (d = 0.29, p = 9 × 10⁻⁴) volumes relative to controls. There were nominally significant differences for amygdala (schizophrenia: d = −0.19, p = .029; affective psychosis: d = −0.31, p = .026), thalamus (schizophrenia: d = −0.19, p = .031), accumbens (affective psychosis: d = −0.29, p = .041), caudate (schizophrenia: d = 0.19, p = .029; other psychosis: d = 0.31, p = .024), and lateral ventricle (affective psychosis: d = 0.32, p = .024; other psychosis: d = 0.27, p = .048; Figure 2, Table S9) volumes. In split-hemisphere analyses, early-onset schizophrenia showed significantly lower hippocampal (left: d = −0.23, p = .008) and higher pallidum (left: d = 0.28, p = .001; right: d = 0.24, p = .006) volumes, while affective psychosis showed lower left accumbens (d = −0.39, p = .005) volume (Tables S10 and S11).

3.4 | Age at onset and illness duration

There were no significant effects of age at onset or duration of illness on the included regional brain volumes in EOP (Tables S12 and S13).
3.5 | Antipsychotic medication

When stratifying patients based on current antipsychotic medication use, users ($n = 193$) had significantly lower ICV ($d = −0.42$, $p = 2 \times 10^{−6}$), and nominally significant lower hippocampal, and higher caudate, pallidum, and lateral ventricular volumes relative to controls (Figure 3, Table S14). In split-hemisphere analyses, antipsychotic users showed significantly higher left caudate ($d = 0.24$, $p = .006$) and pallidum ($d = 0.26$, $p = .003$) volumes compared to controls. Non-users ($n = 39$) showed nominally significant lower hippocampal volume.

Direct comparison between antipsychotic users/non-users showed no significant volumetric differences (Table S15).

4 | DISCUSSION

In this mega-analysis, we found a structural brain signature characterized by significantly lower ICV and hippocampal volumes, and higher caudate and pallidum volumes in EOP compared to healthy controls. Lower ICV featured in both early-onset schizophrenia and affective...
psychosis, while lower hippocampal and higher pallidum volumes were limited to schizophrenia. Enlarged left caudate and pallidum volumes were observed in patients currently on antipsychotic treatment. The most striking finding was the lower ICV in patients with EOP ($d = -0.39$). This effect was larger than the lower ICV reported in a meta-analysis of adult schizophrenia ($d = -0.12; \text{van Erp et al., 2016}$), and no such effect was reported for adult bipolar disorders (Hibar et al., 2016) (Figure 4a). ICV expands rapidly in early age, driven by brain growth, and is thought to reach 90% of its final volume by early adolescence (Courchesne et al., 2000; Haijma et al., 2013). A study combining multiple longitudinal samples found evidence for continued ICV expansion, with an estimated annual increase of ~1% from late childhood to mid-adolescence, with stabilization in late adolescence (Mills et al., 2016). Given the relative stability of ICV from mid-adolescence onwards, our findings of lower ICV in EOP suggest an aberrant neurodevelopment, which is more severe and/or established earlier than in adult-onset psychosis.

Interestingly, a prior multisite study found lower ICV in ADHD ($d = -0.10$), with strongest effects among children ($d = -0.14$) and adolescents ($d = -0.13$; not significant; Hoogman et al., 2017), which is smaller than the effect size observed in EOP ($d = -0.39$; Figure 4b). In contrast, higher ICV was reported in ASD ($d = 0.13$; van Rooij et al., 2018), indicating differential neurodevelopmental mechanisms. Our findings further highlight the importance of considering ICV in imaging studies of neurodevelopmental disorders, and suggest the need for research into early mechanisms influencing smaller head development, including longitudinal studies and normative modeling (Wolfers et al., 2018) of growth patterns from birth, and their relationship to cognitive development and functioning.

The subcortical signature of EOP appeared similar to that of adult schizophrenia (van Erp et al., 2016) and bipolar disorder (Hibar et al., 2016) relative to controls (Figure 4a). Similarities included lower hippocampal, and higher pallidum (schizophrenia only) and lateral ventricular (nominally significant in EOP) volumes; except for pallidum, effect sizes were less pronounced than in schizophrenia. Additionally, we confirmed the higher caudate volumes, as previously observed in EOP (Frazier et al., 1996b; Juuhl-Langseth et al., 2012). Generally, the magnitude of subcortical differences in EOP relative to controls appeared greater than those reported in the ADHD (Hoogman et al., 2017) or ASD (van Rooij et al., 2018) samples, and the directionality of effects were similar for limbic structures, while opposing for basal ganglia structures (Figure 4b).

The hippocampus showed the lowest volume in EOP relative to controls, in agreement with findings in adult schizophrenia (van Erp et al., 2016) and bipolar disorder (Hibar et al., 2016). The effect size ($d = -0.25$) was similar to those reported in bipolar disorder ($d = -0.23; \text{Hibar et al., 2016}$), but smaller than in schizophrenia ($d = -0.46; \text{van Erp et al., 2016}$). Lower hippocampal volume was also reported in children ($d = -0.12; \text{<15 years}$) and adolescents ($d = -0.24; \text{age-range 15–21 years}$) with ADHD (Hoogman et al., 2017). Thus, lower hippocampal volume features across several neurodevelopmental disorders, and may reflect both shared and distinct illness mechanisms. Adult studies have shown hippocampal subfield alterations in schizophrenia and bipolar disorder (Haukvik et al., submitted 2020; Haukvik, Tannes, Söderman, & Ågarutz, 2018). Future EOP studies should track volumetric change across the illness course and perform fine-scale mapping to advance our understanding of both the timing and location of hippocampal disruption in neurodevelopmental disorders.
Our finding of lateral ventricular enlargement in EOP (nominally significant combined structure, significant left hemisphere) corresponded closely with the adult literature, but showed a smaller effect size than reported for both adult schizophrenia (van Erp et al., 2016) and bipolar disorder (Hibar et al., 2016). Prior studies indicate progressive ventricular expansion across the illness course (Kempton, Stahl, Williams, & DeLisi, 2010). Thus, the short illness duration of patients with EOP could explain the smaller effect size, but longitudinal studies are needed to examine this possibility.

In contrast to studies on adult schizophrenia (van Erp et al., 2016), we did not detect significantly lower amygdala, thalamus and accumbens, or higher putamen volumes. However, we observed trends in the same direction and therefore cannot rule out that the smaller sample size or short duration of illness could explain some of these differences. Further, when omitting ICV as a fixed-effects variable, these volumes (except putamen) were significantly lower than in controls. Since EOP shows larger effect sizes for ICV than for adult schizophrenia (van Erp et al., 2016), adjusting for ICV may partly explain the difference in results. This suggests that the relative difference for amygdala, thalamus and accumbens volumes is larger in EOP versus adolescent controls, than for adult schizophrenia.

In the subgroup analyses, we observed lower ICV in both early-onset schizophrenia and affective psychosis. Significantly lower hippocampal and higher pallidum volumes were limited to early-onset schizophrenia, while lower left accumbens was observed in affective psychosis. Since most patients had a diagnosis of early-onset psychosis.
schizophrenia, the subgroup differences may be explained by the unbalanced sizes of the subgroups. Indeed, comparable effect sizes were observed for hippocampal volume in early-onset schizophrenia ($d = -0.24; n = 183$) and affective psychosis ($d = -0.23; n = 39$); although not significant in affective psychosis. The supplementary meta-analysis suggests a great degree of heterogeneity across the included samples, which could reflect differences in inclusion and exclusion procedures and criteria, or subgroup differences, resulting in variable representation. This further highlights the necessity for large samples when characterizing heterogeneous disorders composed of clinically diverse subgroups.

Our findings of significantly enlarged left pallidum and caudate volumes, and trends towards enlarged putamen volumes in antipsychotic medicated patients suggest similar medication effects on brain structure in adolescents and adults. Intriguingly, the significantly higher caudate volume seen in EOP was not observed in adult schizophrenia (van Erp et al., 2016) or bipolar disorder (Hibar et al., 2016). In past meta-analyses of schizophrenia (Hajima et al., 2013; Keshavan et al., 1994), lower caudate volumes were seen in antipsychotic-naive patients but not in medicated patients. We did not find lower caudate volume in non-medicated patients compared to controls, which may point to a relative conservation of caudate volume in early-onset compared to adult-onset psychosis. However, the proportion of patients not using antipsychotics was low; therefore, the comparisons between users and non-users may have been underpowered. Furthermore, we could not ascertain that the non-medicated patients were naive to previous antipsychotic medication. In a previous study of early-onset schizophrenia, the enlarged caudate volumes were not linked to antipsychotic medication use (Juuhl-Langseth et al., 2012), while in adolescents with childhood-onset schizophrenia who initially were on typical neuroleptics, caudate enlargement declined following clozapine treatment (Frazier et al., 1996b).

This study had some limitations. The cross-sectional design precluded the investigation of developmental trajectories. Data was collected from different sites, and site-wise differences in diagnostic routines and MRI acquisition may influence the results. ICV and height show genetic correlation (Adams et al., 2016). We did not have information on height/weight, and could not test whether small body size explained the ICV differences. The validity of the FreeSurfer estimated ICV has been questioned (Heinen et al., 2016; Klassen, Olsson, Eckerström, Malmgren, & Wallin, 2018), and it is an indirect measure of the intracranial volume. In the medication analysis, we did not adjust for patient subgroup or illness severity that may influence the results. We could not ascertain possible prior antipsychotic use in current non-users, nor putative effects of cumulative antipsychotic exposure, antipsychotic type and dosage, age at initial treatment, or the effects of lithium and other mood stabilizers.

Strengths of this study include the hitherto largest adolescent EOP sample, harmonized and validated ENIGMA MRI processing protocols, and a mega-analytical approach previously shown to be more sensitive than meta-analysis (Boedhoe et al., 2019). The standardized analysis pipeline enabled comparative discussion with results from prior ENIGMA studies. Patients with EOP likely have shorter illness duration, less treatment exposure, shorter history of adverse lifestyle, and less alcohol/substance use, compared to adult patients. Thus, the influence of these confounding variables should be comparably smaller than in adult samples.

5 | CONCLUSION

The pattern of volumetric differences in EOP overlapped with, but also showed notable deviations from findings as previously demonstrated in adult psychosis studies. Particularly, the large effect size for ICV may point to a greater involvement of neurodevelopmental mechanisms in EOP, possibly serving as a predictor for early psychosis risk. Future studies should investigate the biological mechanisms of low ICV to identify potential risk markers and targets for differential psychiatric treatment in EOP. This study illustrates the benefits of large-scale international collaborative efforts in characterizing brain structural abnormalities in rare disorders and lays the groundwork for future studies of the neural foundations for EOP.

ACKNOWLEDGMENTS

ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, S10OD023696. YTOP: The Research Council of Norway (#222373, #2137000, #250358, #288083); South-Eastern Norway Regional Health Authority (#2017112); KG Jøbsen Stiftelsen (#SKGI-MED-008). Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission, “A way of making Europe”; CIBERSAM: Instituto de Investigación Sanitaria Gregorio Marañón; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7-HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS); Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. Covadonga M. Díaz-Caneja holds a grant from Instituto de Salud Carlos III (UR19/000024). UCLA: NIH/NIBIB U54 EB020403 (BD2K); NIMH RO3 MH105808; P50MH066286; Staglin Family/IMHRO Music Festival for Mental Health. Deakin: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (#521-2014-3487, #2017-00949); FORMAS (#259-2012-31). KCL-2: Netherland Organization for Scientific Research (NWO: #451-13-035 to Anne-Kathrin J. Fett and #453-11-005 to Lydia Krabbenand); NARSAD Young Investigator Award from the Brain and Behavior Foundation (#24138 to Anne-
Kathrin J. Fett), KCL-1: R01MH113619. Brain and Behavior Research Foundation/NARSAD. SRI: Canadian Institutes of Health Research; Ontario Mental Health Foundation; Brain & Behavior Research Foundation/NARSAD. Oxford: MRC G0500092. MEND: NIMH R01 MH101506. UIO PSI: South-Eastern Norway Regional Health Authority grants to Bjørn R. Rund (#2004-259, #2006-186). We thank the research team and participants at each contributing site for the opportunity to conduct this research. This work was performed on Services for sensitive data (TSD), IT-department (USIT), University of Oslo, Norway, with resources provided by UNINETT Sigma2—the National Infrastructure for High Performance Computing and Data Storage in Norway.

CONFLICT OF INTEREST
Celso Arango: has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda; Covadonga M. Diaz-Caneja: has received honoraria from AbbVie, Sanofi, and Exeltis; Michael Berk: was supported by an unrestricted grant from AstraZeneca; Paul M. Thompson, Neda Jahanshad: MPI of a research grant from Biogen, Inc., for work unrelated to the contents of this manuscript. Ole A. Andreassen: has received speaker’s honorarium from Lundbeck, and is a consultant to HealthLytix. Bradley J. MacIntosh: received a NARSAD Independent Investigator award from the Brain Behavior Research Foundation.

AUTHOR CONTRIBUTIONS

DATA AVAILABILITY STATEMENT
The datasets from this study will not be made publicly available as we do not have approvals for sharing clinical data.

ORCID
Tiril P. Gurholt https://orcid.org/0000-0002-1272-7616
Unn K. Haukvik https://orcid.org/0000-0002-0363-4127
Claudia Barth https://orcid.org/0000-0001-6544-0945
Covadonga M. Diaz-Caneja https://orcid.org/0000-0001-8538-3175
Marinos Kyriakopoulos https://orcid.org/0000-0002-4594-2646
Bradley J. MacIntosh https://orcid.org/0000-0001-7300-2355
Runar E. Smelror https://orcid.org/0000-0001-8611-6132
Christian K. Tannes https://orcid.org/0000-0002-9191-6764
Sophia I. Thomopoulos https://orcid.org/0000-0002-0046-4070
Kirsten Wedervang-Resell https://orcid.org/0000-0002-2856-5412

ENDNOTE
1 A meta-analysis aggregates summary results (e.g., effect size estimates and confidence intervals) across studies, while a mega-analysis aggregates individual participant data across cohorts. For an empirical comparison of the two techniques using structural MRI data, see Boedhoe et al. (2019).

REFERENCES


**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Gurholt TP, Lonning V, Nerland S, et al. Intracranial and subcortical volumes in adolescents with early-onset psychosis: A multisite mega-analysis from the ENIGMA consortium. *Hum Brain Mapp.* 2022;43:373–384. [https://doi.org/10.1002/hbm.25212](https://doi.org/10.1002/hbm.25212)